Centessa Pharmaceuticals plc (CNTA)
NASDAQ: CNTA · Real-Time Price · USD
16.81
-0.36 (-2.10%)
At close: Aug 1, 2025, 4:00 PM
17.73
+0.92 (5.47%)
After-hours: Aug 1, 2025, 7:53 PM EDT

Company Description

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines.

Its lead clinical-stage program includes ORX750, an orally administered OX2R agonist in a Phase 2a study for the treatment of idiopathic hypersomnia and narcolepsy type 1 and 2.

The company also develops ORX142 for the treatment of neurological and neurodegenerative disorders, as well as other potential symptoms, including excessive daytime sleepiness, impaired attention, cognitive deficits, and fatigue; and ORX489 for the treatment of neuropsychiatric disorders.

In addition, it offers LockBody, which is designed to selectively drive potent effector function activity, such as CD3, into the tumor microenvironment.

Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.

Centessa Pharmaceuticals plc
Centessa Pharmaceuticals logo
CountryUnited Kingdom
Founded2020
IPO DateMay 28, 2021
IndustryBiotechnology
SectorHealthcare
Employees77
CEOSaurabh Saha

Contact Details

Address:
1 Ashley Road, 3rd Floor
Altrincham, WA14 2DT
United Kingdom
Websitecentessa.com

Stock Details

Ticker SymbolCNTA
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
IPO Price$20.00
CIK Code0001847903
CUSIP Number152309100
ISIN NumberUS1523091007
SIC Code2834

Key Executives

NamePosition
Dr. Saurabh Saha M.D., Ph.D.Chief Executive Officer and Director
John J. Crowley CPAChief Financial Officer and Principal Financial Officer
Iqbal J. Hussain L.L.B.General Counsel, Chief Compliance Officer and Corporate Secretary
Raphael Deferiere CPAChief Accounting Officer and Principal Accounting Officer
Tia L. BushChief Technology and Quality Officer
Kristen K. Sheppard Esq., J.D.Senior Vice President of Investor Relations and Corporate Communications
Karen M. AndersonChief People Officer
Dr. Gregory M. Weinhoff M.B.A., M.D.Chief Business Officer
Dr. Mario Alberto Accardi Ph.D.President of the Orexin Program
Charlene StoudtSenior Vice President of Clinical Development Operations

Latest SEC Filings

DateTypeTitle
Jul 29, 2025144Filing
Jul 25, 2025144Filing
Jul 21, 2025144Filing
Jul 17, 2025144Filing
Jul 17, 2025144Filing
Jul 15, 2025144Filing
Jun 25, 2025144Filing
Jun 25, 2025144Filing
Jun 24, 2025144Filing
Jun 20, 2025144Filing